Method
Each article starts from the primary literature, not from other websites. For CJC-1295 that is the ConjuChem chemistry paper of 2005 and the two Journal of Clinical Endocrinology and Metabolism trials of 2006; for ipamorelin it is the Novo Nordisk paper of 1998, the pharmacokinetic study of 1999 and the phase 2 trials registered by Helsinn; for the GHRH plus GHRP principle it is the 1990 study by Bowers and Thorner. Abstracts are read from PubMed; registry entries are read from the ClinicalTrials.gov API. When a figure is quoted, it is the figure in the abstract or the registry entry, in the units the authors used.
Before publication, every DOI on the site is requested from the CrossRef API at api.crossref.org and every trial number from the ClinicalTrials.gov API; a reference that does not return HTTP 200 is not cited. As of the last check, the site cites 24 sources, 19 of them with a DOI and 5 with a registry number. Regulatory statements point to the FDA and WADA pages they come from.
What the site will not do
- It does not give protocols. Doses appear only as the doses of the published studies, with the DOI beside them, and are reported rather than recommended.
- It does not publish testimonials, reviews, before-and-after accounts or personal results, because none exist in the literature for these molecules and inventing them would be a lie.
- It does not describe effects on muscle, fat, sleep or recovery for CJC-1295 ipamorelin, because no human study has measured them.
- It carries no analytics, no advertising pixel and no third-party script.
Why it links to one supplier page
Readers who reach the end of an article often want to know what a properly documented vial looks like. Rather than list ten suppliers it cannot vouch for, the site links to one product page, the CJC-1295 / ipamorelin blend at oxpeptides.com, because that page names the form (Mod GRF 1-29), states the two masses and publishes the certificate of analysis for each lot. The link is not sponsored, is not an affiliate link, and earns nothing. The criteria behind it are set out in CJC-1295 ipamorelin for sale; if the page stops meeting them, the link will be removed.
Corrections
Errors are corrected on the page where they occur, with the updated date changed, and a note is added at the foot of the page when the correction changes a figure. Reports go to editor@cjc-1295-ipamorelin.com; a report that cites a DOI or an NCT number is answered first. The full policy is on the editorial policy page.
Who
The site is written and maintained by its editorial team, which is unaffiliated with any clinic, pharmacy or manufacturer named on it. It does not publish personal bylines. The publisher of record is CJC-1295 Ipamorelin Review, reachable at the address above.
All 12 articles
- CJC-1295 ipamorelin dosage: the doses that were actually studied
- CJC-1295 DAC vs no DAC: what 279 daltons change
- Mod GRF 1-29: a forum name for a laboratory molecule
- Ipamorelin peptide: the selective secretagogue that reached phase 2
- Ipamorelin side effects: what was measured, not what is rumoured
- Sermorelin vs CJC-1295 ipamorelin: three molecules, one axis
- CJC-1295 ipamorelin for sale: the nine things a listing must say
- CJC-1295 peptide: from a ConjuChem bench to two human trials
- CJC-1295 ipamorelin vs tesamorelin: the approved one and the other two
- What is CJC-1295 ipamorelin? Two receptors, one pulse
- CJC-1295 ipamorelin on Reddit: the seven questions that keep coming back
- CJC-1295 side effects: the human record, dose by dose
Informational content, not medical advice. CJC-1295 and ipamorelin are investigational research compounds, not approved by the FDA or the EMA for any use.